2016GliaRequires access

Critical data‐based re‐evaluation of minocycline as a putative specific microglia inhibitor

Thomas Möller, Frédérique Bard, Anindya Bhattacharya, Knut Biber, Brian Campbell, Elena Dale, Claudia Eder, Li Gan, Gwenn A. Garden, Zoë A. Hughes, Damien D. Pearse, Roland G. W. Staal, Faten A. Sayed, Paul D. Wes, Hendrikus Boddeke

Open publisher page 204 citations

Abstract

Minocycline, a second generation broad-spectrum antibiotic, has been frequently postulated to be a "microglia inhibitor." A considerable number of publications have used minocycline as a tool and concluded, after achieving a pharmacological effect, that the effect must be due to "inhibition" of microglia. It is, however, unclear how this "inhibition" is achieved at the molecular and cellular levels. Here, we weigh the evidence whether minocycline is indeed a bona fide microglia inhibitor and discuss how data generated with minocycline should be interpreted. GLIA 2016;64:1788-1794.

About this research paper

What this paper is about

Minocycline, a second generation broad-spectrum antibiotic, has been frequently postulated to be a "microglia inhibitor." A considerable number of publications have used minocycline as a tool and concluded, after achieving a pharmacological effect, that the effect must be due to "inhibition" of microglia. It is, however, unclear how this "inhibition" is achieved at the molecular and cellular levels. Here, we weigh the evidence whether minocycline is indeed a bona fide microglia inhibitor and discuss how data generated with minocycline should be interpreted. GLIA 2016;64:1788-1794.

Why it matters

OpenAlex reports 204 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Minocycline, a second generation broad-spectrum antibiotic, has been frequently postulated to be a "microglia inhibitor." A considerable number of publications have used minocycline as a tool and concluded, after achieving a pharmacological effect, that the effect must be due to "inhibition" of microglia. It is, however, unclear how this "inhibition" is achieved at the molecular and cellular levels. Here, we weigh the evidence whether minocycline is indeed a bona fide microglia inhibitor and discuss how data generated with minocycline should be interpreted. GLIA 2016;64:1788-1794.

Key concepts: Minocycline, Microglia, Biology, Neuroscience, Bioinformatics, Antibiotics, Pharmacology, Immunology

Related papers

Back to paper searchBrowse research topicsOriginal source
Critical data‐based re‐evaluation of minocycline as a putative specific microglia inhibitor — Research Paper | ScholarLens